NOZ Xenograft Model Service for Biliary Tract Cancer

The NOZ xenograft model represents one of the most extensively validated preclinical platforms for biliary tract cancer research, enabling robust evaluation of therapeutic candidates in an immunodeficient host environment. Alfa Cytology delivers comprehensive NOZ xenograft model development and characterization services, leveraging rigorous quality control standards and standardized protocols to accelerate your preclinical drug discovery programs from target validation to candidate selection.

Overview of NOZ Xenograft Model for Biliary Tract Cancer

The NOZ cell line, originally established from the ascites of a 48-year-old Japanese female patient diagnosed with gallbladder carcinoma, has become a cornerstone cell-based model for studying biliary tract malignancies. As the most common malignancy of the biliary system, gallbladder cancer (GBC) is characterized by aggressive biological behavior, early lymphatic metastasis, and a dismal 5-year survival rate of approximately 5%. The NOZ xenograft model faithfully recapitulates these malignant phenotypes, demonstrating consistent tumorigenicity in immunodeficient mice with moderately differentiated histopathological features comparable to primary human GBC tissues.

Preclinical studies utilizing the NOZ xenograft platform have demonstrated its utility across multiple therapeutic modalities, including chemotherapy sensitization studies, targeted agent evaluation, and combination regimen assessment. The model exhibits reliable tumor growth kinetics with typical inoculum concentrations of 1x10⁵ to 2x10⁶ cells, enabling standardized tumor volume monitoring and endpoint analysis. Furthermore, the NOZ model has been successfully adapted for both subcutaneous and orthotopic implantation strategies, with orthotopic variants providing enhanced clinical relevance through gallbladder microenvironment recapitulation and spontaneous metastasis patterns.

Figure 1. NOZ GemR cells exhibit changes in EMT marker expression and the Akt/mTOR signaling pathway. (Xu, M, et al., 2024)

Cell Line Information: NOZ

The NOZ cell line is a well-characterized human gallbladder carcinoma cell line established from ascitic fluid, widely utilized in preclinical oncology research for its faithful representation of biliary tract malignancy biology and robust xenograft formation capacity.

Our Services

Alfa Cytology provides end-to-end NOZ xenograft model services encompassing cell line authentication, inoculum preparation, animal welfare-compliant implantation procedures, longitudinal tumor monitoring, and comprehensive endpoint analysis including tumor growth curves, body weight tracking, histopathological evaluation, and immunohistochemical biomarker assessment. Our experienced scientific team ensures protocol reproducibility and data integrity across all study phases, delivering publication-ready datasets tailored to your specific research objectives.

Workflow of NOZ Xenograft Model Construction

The construction of NOZ xenograft models at Alfa Cytology follows a systematic, quality-controlled workflow designed to maximize model reliability and data reproducibility. Each project begins with thorough cell line authentication and health monitoring, proceeding through standardized implantation procedures and rigorous post-implantation care protocols.

1. Cell Line Authentication and Quality Control: NOZ cells are authenticated via STR profiling and routinely tested for mycoplasma contamination prior to expansion. Cells are maintained in DMEM high glucose medium supplemented with 10% fetal bovine serum under standard culture conditions.
2. Inoculum Preparation: Cells are harvested at logarithmic growth phase using 0.25% trypsin-EDTA, washed with sterile PBS, and resuspended at predetermined concentrations (typically 1x10⁵ to 2x10⁶ cells in 100 uL PBS or Matrigel mixture for enhanced engraftment).
3. Animal Preparation and Implantation: Immunodeficient mice (BALB/c nude or NCG/NSG strains) are acclimatized for one week. For subcutaneous models, cell suspensions are injected into the flank region. For orthotopic models, cells mixed with Matrigel are surgically implanted into the gallbladder wall via abdominal midline incision under appropriate anesthesia.
4. Post-Implantation Monitoring: Mice are monitored daily during the first week and every three days thereafter. Tumor dimensions are measured using digital calipers, with volume calculated as (length x width²)/2.
5. Treatment Administration and Efficacy Assessment: Upon reaching target tumor volume (typically 100--200 mm³), mice are randomized into treatment and control groups. Test compounds are administered via intraperitoneal injection, oral gavage, or other specified routes according to study design.
6. Endpoint Analysis and Data Collection: At study termination, tumors are excised, weighed, and processed for histopathological analysis (H&E staining, IHC, TUNEL assay) and molecular profiling (Western blot, qPCR) as required.

Figure 2. NOZ xenograft model construction workflow.

Case Study-NOZ Xenograft Model Development

Alfa Cytology has successfully developed and validated NOZ xenograft models for multiple preclinical therapeutic programs targeting biliary tract malignancies. Our internal case studies demonstrate consistent tumor engraftment rates, predictable growth kinetics, and responsive pharmacodynamic readouts suitable for evaluating novel therapeutic candidates. Detailed efficacy data, tumor growth profiles, and histopathological findings are available upon request through our scientific team. Contact us to schedule a confidential data review session tailored to your specific drug development requirements.

Why Choose Alfa Cytology?

Alfa Cytology stands as a trusted preclinical CRO partner for biliary tract cancer xenograft model development, combining scientific expertise with operational excellence to advance your therapeutic pipeline.

• Comprehensive Model Portfolio: We offer both subcutaneous and orthotopic NOZ xenograft configurations, enabling selection of the most clinically relevant model for your research objectives.
• Rigorous Quality Standards: All cell lines undergo STR authentication and mycoplasma screening; animal studies comply with IACUC guidelines and international welfare standards.
• Customized Study Design: Our team collaborates with you to design tailored dosing regimens, combination strategies, and endpoint analyses aligned with your development milestones.
• Publication-Ready Data Delivery: We provide comprehensive study reports including statistical analysis, histopathological imaging, and biomarker data formatted for regulatory and scientific communication needs.
• Accelerated Timelines: Standard NOZ xenograft studies can be initiated within 2--3 weeks, with typical study durations of 4--6 weeks depending on treatment arms and endpoints.

Contact Us

Ready to advance your biliary tract cancer therapeutic program with a validated NOZ xenograft model? Contact our scientific team today to discuss your study requirements, review available data packages, and receive a customized project proposal. Reach out to us via email or through our website inquiry form, and let Alfa Cytology accelerate your preclinical journey from concept to candidate.

For research use only. Not intended for any clinical use.